{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:52:05Z","timestamp":1780451525624,"version":"3.54.1"},"reference-count":428,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jval.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:42:32Z","timestamp":1754437352000},"page":"1426-1443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Do We Always Need a New Preference Study? A Scoping Review of Promising Research Areas for Meta-Analyses and Benefit Transfers of Patient Preference Studies"],"prefix":"10.1016","volume":"28","author":[{"given":"Michael","family":"Bui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina G.M.","family":"Groothuis-Oudshoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Cecilia","family":"Jimenez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine A.","family":"van Til","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2025.06.004_bib1","article-title":"Application of discrete choice experiment in health care: a bibliometric analysis","volume":"9","author":"Wang","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.jval.2025.06.004_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocm.2021.100303","article-title":"The landscape of econometric discrete choice modelling research","volume":"40","author":"Haghani","year":"2021","journal-title":"J Choice Modell"},{"key":"10.1016\/j.jval.2025.06.004_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocm.2023.100466","article-title":"The rise of best-worst scaling for prioritization: a transdisciplinary literature review","volume":"50","author":"Schuster","year":"2024","journal-title":"J Choice Modell"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib4","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ddtec.2011.03.002","article-title":"Patient opinions and preferences in drug development and regulatory decision making","volume":"8","author":"Breckenridge","year":"2011","journal-title":"Drug Discov Today Technol"},{"issue":"12","key":"10.1016\/j.jval.2025.06.004_bib5","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.healthpol.2020.07.007","article-title":"An overview of critical decision-points in the medical product lifecycle: where to include patient preference information in the decision-making process?","volume":"124","author":"Whichello","year":"2020","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2025.06.004_bib6","author":"van Overbeeke"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40271-023-00653-8","article-title":"Current practices and challenges when submitting patient experience data for regulatory decisions by the US Food and Drug Administration: an industry survey","volume":"17","author":"Pinto","year":"2024","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40271-017-0222-3","article-title":"Giving patients\u2019 preferences a voice in medical treatment life cycle: The PREFER public\u2013private project","volume":"10","author":"de Bekker-Grob","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.jval.2025.06.004_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1192770","article-title":"How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action","volume":"14","author":"Janssens","year":"2023","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40271-017-0295-z","article-title":"Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis","volume":"11","author":"Gonzalez","year":"2018","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40271-021-00513-3","article-title":"Evaluating the consistency of patient preference estimates: systematic variation in survival-adverse event trade-offs in patients with cancer or cardiovascular disease","volume":"15","author":"Marsh","year":"2022","journal-title":"Patient"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib13","doi-asserted-by":"crossref","DOI":"10.2196\/25959","article-title":"Consumers\u2019 willingness to pay for ehealth and its influencing factors: systematic review and meta-analysis","volume":"24","author":"Xie","year":"2022","journal-title":"J Med Internet Res"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40271-023-00650-x","article-title":"Research priorities to increase confidence in and acceptance of health preference research: what questions should be prioritized now?","volume":"17","author":"DiSantostefano","year":"2024","journal-title":"Patient"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40271-021-00502-6","article-title":"Methodological priorities for patient preferences research: stakeholder input to the prefer public\u2013private project","volume":"14","author":"Smith","year":"2021","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10640-021-00574-w","article-title":"Guidance to enhance the validity and credibility of environmental benefit transfers","volume":"79","author":"Johnston","year":"2021","journal-title":"Environ Resource Econ"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1467-6419.2009.00592.x","article-title":"Methods, trends and controversies in contemporary benefit transfer","volume":"24","author":"Johnston","year":"2010","journal-title":"J Econ Surv"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev.resource.012809.103933","article-title":"The benefit-transfer challenges","volume":"2","author":"Boyle","year":"2010","journal-title":"Annu Rev Resour Econ"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10640-017-0207-7","article-title":"Benefit transfer challenges: perspectives from U.S. practitioners","volume":"69","author":"Newbold","year":"2018","journal-title":"Environ Resour Econ"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/resources2040517","article-title":"Benefit transfer: a review of methodologies and challenges","volume":"2","author":"Boutwell","year":"2013","journal-title":"Resources"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0921-8009(99)00070-1","article-title":"Environmental value transfer: state of the art and future prospects","volume":"32","author":"Brouwer","year":"2000","journal-title":"Ecol Econ"},{"key":"10.1016\/j.jval.2025.06.004_bib22","series-title":"Environmental Value Transfer: Issues and Methods. The Economics of Non-Market Goods and Resources","first-page":"1","article-title":"Review of Methods for Value Transfer","author":"Navrud","year":"2007"},{"key":"10.1016\/j.jval.2025.06.004_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s40273-025-01495-y","article-title":"The evolving landscape of discrete choice experiments in health economics: a systematic review","author":"Nouwens","year":"2025","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib24","first-page":"55","article-title":"Using discrete choice experiments to value health care programmes: current practice and future research reflections","volume":"2","author":"Ryan","year":"2003","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hec.1697","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"21","author":"de Bekker-Grob","year":"2012","journal-title":"Health Econ"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"32","author":"Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","article-title":"Discrete Choice experiments in health economics: past, present and future","volume":"37","author":"Soekhai","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40271-020-00434-7","article-title":"Quantitative preferences for lung cancer treatment from the patients\u2019 perspective: a systematic review","volume":"13","author":"Sugitani","year":"2020","journal-title":"Patient"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/j.pain.0000000000002775","article-title":"Patient preferences in the treatment of chronic musculoskeletal pain: a systematic review of discrete choice experiments","volume":"164","author":"Zhu","year":"2023","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40271-019-00375-w","article-title":"Patient preferences for breast cancer treatment interventions: a systematic review of discrete choice experiments","volume":"12","author":"Guerra","year":"2019","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40271-021-00536-w","article-title":"A systematic and critical review of discrete choice experiments in asthma and chronic obstructive pulmonary disease","volume":"15","author":"Collacott","year":"2022","journal-title":"Patient"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jval.2025.06.004_bib33","author":"Bui"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40290-014-0059-1","article-title":"A systematic review to identify the use of preference elicitation methods in healthcare decision making","volume":"28","author":"Weernink","year":"2014","journal-title":"Pharm Med"},{"key":"10.1016\/j.jval.2025.06.004_bib35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2147\/PPA.S362802","article-title":"Patient preference studies for advanced prostate cancer treatment along the medical product life cycle: systematic literature review","volume":"16","author":"Menges","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib36","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","article-title":"Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review","volume":"24","author":"Soekhai","year":"2019","journal-title":"Drug DiscoveryDiscov Today"},{"key":"10.1016\/j.jval.2025.06.004_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jclinepi.2020.10.007","article-title":"Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews","volume":"130","author":"Garritty","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.dss.2004.04.009","article-title":"Market basket analysis in a multiple store environment","volume":"40","author":"Chen","year":"2005","journal-title":"Decis Support Syst"},{"issue":"15","key":"10.1016\/j.jval.2025.06.004_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v014.i15","article-title":"arules-a computational environment for mining association rules and frequent item sets","volume":"14","author":"Hahsler","year":"2005","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jval.2025.06.004_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.vhri.2020.10.002","article-title":"Preferences of patients with HR+ and HER2- breast cancer regarding hormonal and targeted therapies in the first line of their metastatic stage: a discrete choice experiment","volume":"25","author":"Nazari","year":"2021","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bjps.2010.04.030","article-title":"Patients\u2019 preferences for breast reconstruction: a discrete choice experiment","volume":"64","author":"Damen","year":"2011","journal-title":"J Plast Reconstr Aesthetic Surg"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10549-014-2909-7","article-title":"Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine","volume":"145","author":"Smith","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib45","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/s40064-015-1482-9","article-title":"Patients\u2019 preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments","volume":"4","author":"Ngorsuraches","year":"2015","journal-title":"Springerplus"},{"key":"10.1016\/j.jval.2025.06.004_bib46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.breast.2016.02.015","article-title":"Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care","volume":"27","author":"Kool","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.jval.2025.06.004_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fonc.2018.00535","article-title":"Patient preferences regarding chemotherapy in metastatic breast cancer\u2014a conjoint analysis for common taxanes","volume":"8","author":"Spaich","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib48","first-page":"1","article-title":"The value of progression-free survival in metastatic breast cancer: results from a survey of patients and providers","volume":"4","author":"Macewan","year":"2019","journal-title":"MDM Policy Pract"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib49","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12282-019-00965-4","article-title":"Patients\u2019 preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan","volume":"26","author":"Omori","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jval.2025.06.004_bib50","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/PPA.S254934","article-title":"Oncologist and patient preferences for attributes of cdk4\/6 inhibitor regimens for the treatment of advanced\/metastatic HR positive\/HER2 negative breast cancer: discrete choice experiment and best\u2013worst scaling","volume":"14","author":"Maculaitis","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib51","article-title":"Do patient preferences align with value frameworks? a discrete-choice experiment of patients with breast cancer","volume":"5","author":"Hollin","year":"2020","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.jval.2025.06.004_bib52","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/PPA.S298670","article-title":"Patient, oncologist, and payer preferences for adjuvant endocrine therapy and CDK4\/6 inhibitor regimens in early-stage breast cancer: a discrete choice experiment","volume":"15","author":"Beusterien","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.33287","article-title":"Quantifying treatment preferences and their association with financial toxicity in women with breast cancer","volume":"127","author":"Williams","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib54","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2217\/fon-2021-0635","volume":"18","author":"Stamuli","year":"2022","journal-title":"Future Oncol"},{"issue":"16","key":"10.1016\/j.jval.2025.06.004_bib55","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2217\/fon-2021-0761","article-title":"Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives","volume":"18","author":"Amin","year":"2022","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12282-022-01394-6","article-title":"Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study","volume":"30","author":"Mansfield","year":"2023","journal-title":"Breast Cancer"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076798","article-title":"Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment","volume":"14","author":"Bullen","year":"2024","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib58","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.euo.2024.06.010","article-title":"Patients\u2019 preferences for cytoreductive treatments in newly diagnosed metastatic prostate cancer: the IP5-MATTER study","volume":"8","author":"Connor","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jval.2025.06.004_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijnurstu.2024.104695","article-title":"Patient preferences and willingness to pay for central venous access devices in breast cancer: a multicenter discrete choice experiment","volume":"152","author":"Liu","year":"2024","journal-title":"Int J Nurs Stud"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib60","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462323000168","article-title":"Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis","volume":"39","author":"Stamuli","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib61","article-title":"What Drives Patient Choice: Preferences for Approaches to Surgical Treatments for Breast Cancer Beyond Traditional Clinical Benchmarks","volume":"6","author":"Storm-Dickerson","year":"2018","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.jval.2025.06.004_bib62","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/IJWH.S31331","article-title":"Patient preferences for chemotherapies used in breast cancer","volume":"4","author":"Beusterien","year":"2012","journal-title":"Int J Womens Health"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib63","article-title":"Patient preferences for adjuvant radiotherapy in early breast cancer are strongly influenced by treatment received through random assignment","volume":"28","author":"Corica","year":"2019","journal-title":"Eur J Cancer Care"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib64","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1093\/annonc\/mdt195","article-title":"Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer","volume":"24","author":"Wouters","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1634\/theoncologist.2013-0359","article-title":"Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects","volume":"19","author":"Beusterien","year":"2014","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib66","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1055\/s-0042-101025","article-title":"Targets for neoadjuvant therapy - the preferences of patients with early breast cancer","volume":"76","author":"Thill","year":"2016","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000513139","article-title":"Patient preferences: results of a German adaptive choice-based conjoint analysis (Market Research Study Sponsored by Eli Lilly and Company) in patients on palliative treatment for advanced breast cancer","volume":"16","author":"Reinisch","year":"2021","journal-title":"Breast Care"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072469","article-title":"Assessment of patients\u2019 preferences for new anticancer drugs in China: a best\u2013worst discrete choice experiment on three common cancer types","volume":"13","author":"Feng","year":"2023","journal-title":"BMJ Open"},{"issue":"7436","key":"10.1016\/j.jval.2025.06.004_bib69","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/bmj.37972.497234.44","article-title":"Patients\u2019 preferences for the management of non-metastatic prostate cancer: discrete choice experiment","volume":"328","author":"Sculpher","year":"2004","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib70","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/bjc.2011.552","article-title":"Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer","volume":"106","author":"King","year":"2012","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib71","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/bjc.2013.370","article-title":"Patients\u2019 and urologists\u2019 preferences for prostate cancer treatment: a discrete choice experiment","volume":"109","author":"De Bekker-Grob","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12894-016-0182-2","article-title":"Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment","volume":"16","author":"Uemura","year":"2016","journal-title":"BMC Urol"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib73","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.clinthera.2017.02.009","article-title":"Patients\u2019 preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment","volume":"39","author":"Eliasson","year":"2017","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib74","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/1557988318776123","article-title":"Patient preferences and urologist judgments on prostate cancer therapy in Japan","volume":"12","author":"Nakayama","year":"2018","journal-title":"Am J Men\u2019s Health"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib75","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12325-018-0861-3","article-title":"Patient preferences for metastatic hormone-sensitive prostate cancer treatments: a discrete choice experiment among men in three European countries","volume":"36","author":"de Freitas","year":"2019","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib76","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JU.0000000000000754","article-title":"Evaluating the trade-offs men with localized prostate cancer make between the risks and benefits of treatments: the COMPARE study","volume":"204","author":"Watson","year":"2020","journal-title":"J Urol"},{"issue":"18","key":"10.1016\/j.jval.2025.06.004_bib77","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1002\/cam4.3321","article-title":"Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment","volume":"9","author":"Srinivas","year":"2020","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib78","first-page":"367.e7","article-title":"Patients\u2019 preferences for delaying metastatic castration-resistant prostate cancer: combining health state and treatment valuation","volume":"39","author":"Rentz","year":"2021","journal-title":"Urol Oncol Semin Orig Invest"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052471","article-title":"Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment","volume":"11","author":"Uemura","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib80","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.prro.2021.08.012","article-title":"One fraction size does not fit all: patient preferences for hypofractionated radiation therapy from a discrete choice experiment","volume":"12","author":"Sigurdson","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib81","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1002\/cam4.5313","article-title":"Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: a US patient preference survey","volume":"12","author":"George","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jval.2025.06.004_bib82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euros.2023.03.001","article-title":"Patient and general population preferences regarding the benefits and harms of treatment for metastatic prostate cancer: a discrete choice experiment","volume":"51","author":"Menges","year":"2023","journal-title":"Eur Uro Op Sci"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102254","article-title":"Patient preferences for metastatic prostate cancer treatment: a discrete choice experiment","volume":"23","author":"Hong","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102113","article-title":"Patient preferences for benefit and risk associated with high intensity focused ultrasound for the ablation of prostate tissue in men with localized prostate cancer","volume":"22","author":"Babalola","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib85","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1007\/s12325-024-02955-1","article-title":"Patient preferences for attributes of androgen deprivation therapies in prostate cancer: a discrete choice experiment with latent class analysis","volume":"41","author":"Hauber","year":"2024","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib86","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40271-023-00638-7","article-title":"Discrete-choice experiment to understand the preferences of patients with hormone-sensitive prostate cancer in the USA, Canada, and the UK","volume":"16","author":"Gonzalez","year":"2023","journal-title":"Patient"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib87","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0272989X19873667","article-title":"Comparison of rating scale, time tradeoff, and conjoint analysis methods for assessment of preferences in prostate cancer","volume":"39","author":"Kaplan","year":"2019","journal-title":"Med Decis Mak"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235616","article-title":"Patient preferences for reducing bowel adverse events following prostate radiotherapy","volume":"15","author":"Mishra","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib89","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1097\/01.ju.0000181829.07078.22","article-title":"A novel computer based expert decision making model for prostate cancer disease management","volume":"174","author":"Richman","year":"2005","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib90","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/cncr.24905","article-title":"Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy","volume":"116","author":"Wilke","year":"2010","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.jval.2025.06.004_bib91","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/pros.22865","article-title":"Patient preferences for treatments to delay bone metastases","volume":"74","author":"Hauber","year":"2014","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib92","article-title":"Patients\u2019 preferences for androgen deprivation therapy in the treatment of intermediate-risk prostate cancer","volume":"7","author":"De","year":"2022","journal-title":"MDM Policy Pract"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib93","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lungcan.2012.01.016","article-title":"Patients\u2019 preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis","volume":"77","author":"Bridges","year":"2012","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib94","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10198-014-0622-4","article-title":"Patients\u2019 preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer","volume":"16","author":"M\u00fchlbacher","year":"2015","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.radonc.2016.09.003","article-title":"Patient preferences regarding prophylactic cranial irradiation: a discrete choice experiment","volume":"121","author":"Lehman","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jval.2025.06.004_bib96","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2147\/PPA.S224529","article-title":"Patient preferences for chemotherapy in the treatment of non-small cell lung cancer: a multicenter discrete choice experiment (DCE) study in China","volume":"13","author":"Sun","year":"2019","journal-title":"Patient Prefer Adherence"},{"issue":"34","key":"10.1016\/j.jval.2025.06.004_bib97","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.2217\/fon-2019-0396","article-title":"Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer","volume":"15","author":"Bridges","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.jval.2025.06.004_bib98","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.2147\/PPA.S248295","article-title":"The value of hope: patients\u2019 and physicians\u2019 preferences for survival in advanced non-small cell lung cancer","volume":"14","author":"Hauber","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib99","article-title":"Non\u2013small cell lung cancer patient preferences for first-line treatment: a discrete choice experiment","volume":"5","author":"MacEwan","year":"2020","journal-title":"MDM Policy Pract"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/03007995.2021.1888707","article-title":"Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment","volume":"37","author":"Janse","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2025.06.004_bib101","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2147\/PPA.S302394","article-title":"Stated preferences in non-small-cell lung cancer: a discrete choice experiment","volume":"15","author":"Meirelles","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2025.06.004_bib102","article-title":"A study of patient preferences for the treatment of non-small cell lung cancer in western China: a discrete-choice experiment","volume":"9","author":"Liu","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.jval.2025.06.004_bib103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/PPA.S338840","article-title":"Patient and caregiver preferences for first-line treatments of metastatic non-small cell lung cancer: a discrete choice experiment","volume":"16","author":"Yong","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6777","article-title":"Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor-mutant non-small cell lung cancer","volume":"13","author":"Hata","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.jval.2025.06.004_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2023.1062830","article-title":"Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives","volume":"14","author":"Oliveri","year":"2023","journal-title":"Front Psychol"},{"key":"10.1016\/j.jval.2025.06.004_bib106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2019.03.009","article-title":"Understanding patients\u2019 values and preferences regarding early stage lung cancer treatment decision making","volume":"131","author":"Sullivan","year":"2019","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.jval.2025.06.004_bib107","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ejca.2015.05.022","article-title":"Patients\u2019 and doctors\u2019 preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: what makes it worthwhile?","volume":"51","author":"Blinman","year":"2015","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib108","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11136-005-0581-4","article-title":"Are chemotherapy patients\u2019 HRQoL importance weights consistent with linear scoring rules? a stated-choice approach","volume":"15","author":"Johnson","year":"2006","journal-title":"Qual Life Res"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047470","article-title":"Discrete choice experiment to evaluate factors that influence preferences for antibiotic prophylaxis in pediatric oncology","volume":"7","author":"Regier","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib110","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3111\/13696998.2013.832257","article-title":"Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer","volume":"16","author":"Miller","year":"2013","journal-title":"J Med Econ"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib111","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.healthpol.2015.09.001","article-title":"Preferences for end-of-life care among community-dwelling older adults and patients with advanced cancer: a discrete choice experiment","volume":"119","author":"Finkelstein","year":"2015","journal-title":"Health Policy"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib112","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3552","article-title":"Parental considerations regarding cure and late effects for children with cancer","volume":"145","author":"Greenzang","year":"2020","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib113","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s12094-019-02216-6","article-title":"Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer","volume":"22","author":"Valent\u00ed","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib114","doi-asserted-by":"crossref","first-page":"E622","DOI":"10.1200\/JOP.19.00551","article-title":"Evaluating patients\u2019 perception of the risk of acute care visits during systemic therapy for cancer","volume":"16","author":"Phillips","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib115","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jval.2021.04.1284","article-title":"Quantifying value of hope","volume":"24","author":"Reed","year":"2021","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib116","article-title":"Preferences for end-of-life care among patients with terminal cancer in China","volume":"5","author":"Leng","year":"2022","journal-title":"Netw Open"},{"issue":"12","key":"10.1016\/j.jval.2025.06.004_bib117","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jval.2023.08.009","article-title":"A longitudinal evaluation of the preferences of patients with advanced cancer for quality of life and survival in Malaysia: a discrete choice experiment","volume":"26","author":"Yong","year":"2023","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib118","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00435382","article-title":"Choices in oncology: factors that influence patients\u2019 treatment preference","volume":"3","author":"Kiebert","year":"1994","journal-title":"Qual Life Res"},{"issue":"14","key":"10.1016\/j.jval.2025.06.004_bib119","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.ejca.2011.04.038","article-title":"Factors affecting treatment choices in paediatric palliative care: comparing parents and health professionals","volume":"47","author":"Tomlinson","year":"2011","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib120","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jval.2022.01.002","article-title":"How do patients value the benefit of minimally invasive surgery in cancer treatment?","volume":"25","author":"Kim","year":"2022","journal-title":"Value Health"},{"issue":"17","key":"10.1016\/j.jval.2025.06.004_bib121","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1002\/cncr.35333","article-title":"Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial","volume":"130","author":"Soto-Perez-de-Celis","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2025.06.004_bib122","article-title":"Evaluating patients\u2019 preferences for multiple myeloma therapy, a discrete-choice-experiment","volume":"5","author":"M\u00fchlbacher","year":"2008","journal-title":"Psychosoc Med"},{"key":"10.1016\/j.jval.2025.06.004_bib123","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/PPA.S183187","article-title":"Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?","volume":"12","author":"Wilke","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2025.06.004_bib124","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/PPA.S259612","article-title":"Myeloma patient value mapping: a discrete choice experiment on myeloma treatment preferences in the UK","volume":"14","author":"Fifer","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib125","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s12885-020-07018-6","article-title":"Alignment of preferences in the treatment of multiple myeloma \u2013 a discrete choice experiment of patient, carer, physician, and nurse preferences","volume":"20","author":"Fifer","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jval.2025.06.004_bib126","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2147\/PPA.S345906","article-title":"Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States","volume":"16","author":"Auclair","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2025.06.004_bib127","author":"Janssens"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib128","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jval.2023.01.016","article-title":"Current health state affected patient preferences more than disease status: a discrete choice experiment in multiple myeloma","volume":"26","author":"Tervonen","year":"2023","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40273-024-01459-8","article-title":"Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment","volume":"43","author":"Syeed","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2025.06.004_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1271657","article-title":"Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment","volume":"10","author":"Thomas","year":"2023","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib131","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","article-title":"Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma","volume":"23","author":"Postmus","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jval.2025.06.004_bib132","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/CMAR.S125245","article-title":"Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment","volume":"9","author":"Gonz\u00e1lez","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jval.2025.06.004_bib133","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2147\/PPA.S138863","article-title":"Therapy preferences of patients with lung and colon cancer: a discrete choice experiment","volume":"11","author":"Schmidt","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib134","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1080\/03007995.2020.1790348","article-title":"Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment","volume":"36","author":"Wong","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib135","first-page":"122","article-title":"Assessment of metastatic colorectal cancer patients\u2019 preferences for biologic treatments in Germany using a discrete choice experiment","volume":"21","author":"Heinemann","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jval.2025.06.004_bib136","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2147\/PPA.S50970","article-title":"Adjuvant chemotherapy for colorectal cancer: age differences in factors influencing patients\u2019 treatment decisions","volume":"7","author":"Jorgensen","year":"2013","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib137","first-page":"154","article-title":"A patient preference study comparing raltitrexed ('\u2018Tomudex\u2019) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes","volume":"8","author":"Young","year":"1999","journal-title":"Eur J Cancer Care"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib138","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00432-015-2073-4","article-title":"Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment","volume":"142","author":"Fu","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib139","article-title":"Patients\u2019 preferences for 3 months vs 6 months of adjuvant chemotherapy for colon cancer","volume":"5","author":"Blinman","year":"2021","journal-title":"JNCI Cancer Spec"},{"key":"10.1016\/j.jval.2025.06.004_bib140","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2147\/PPA.S140226","article-title":"Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment","volume":"11","author":"Liu","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib141","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.3747\/co.26.5085","article-title":"Preferences of Canadian patients and physicians for adjuvant treatments for melanoma","volume":"26","author":"Stellato","year":"2019","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib142","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/fon-2018-0871","article-title":"Patient preferences for treatment of metastatic melanoma","volume":"15","author":"Mansfield","year":"2019","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib143","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/CMR.0000000000000572","article-title":"Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center","volume":"29","author":"Stenehjem","year":"2019","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib144","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3422","article-title":"Patient preferences in adjuvant and palliative treatment of advanced melanoma: a discrete choice experiment","volume":"100","author":"Weilandt","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib145","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40271-023-00635-w","article-title":"Preferences for adjuvant immunotherapy in adults with resected stage III melanoma\u2014a discrete choice experiment","volume":"16","author":"Livingstone","year":"2023","journal-title":"Patient"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib146","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaad.2018.02.059","article-title":"Patients prioritize local recurrence risk over other attributes for surgical treatment of facial melanomas\u2014results of a stated preference survey and choice-based conjoint analysis","volume":"79","author":"Etzkorn","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"17","key":"10.1016\/j.jval.2025.06.004_bib147","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2217\/fon-2020-1193","article-title":"Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique","volume":"17","author":"Mansfield","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.jval.2025.06.004_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.697711","article-title":"Patient preferences for attributes of chemotherapy for lung cancer: discrete choice experiment study in Japan","volume":"12","author":"Sugitani","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2025.06.004_bib149","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/PPA.S235430","article-title":"Analysis of patient preferences in lung cancer \u2013 estimating acceptable tradeoffs between treatment benefit and side effects","volume":"14","author":"Janssen","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib150","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jval.2022.05.003","article-title":"How do treatment preferences of patients with cancer compare with those of oncologists and family members? evidence from a discrete choice experiment in China","volume":"25","author":"Zhang","year":"2022","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.imr.2023.100969","article-title":"Patient preferences and shared decision making for the traditional Chinese medicine treatment of lung cancer: a discrete choice experiment study","volume":"12","author":"Teng","year":"2023","journal-title":"Integr Med Res"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib152","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jval.2020.06.021","article-title":"Measuring the value healthy individuals place on generous insurance coverage of severe diseases: a stated preference survey of adults diagnosed with and without lung cancer","volume":"24","author":"Shafrin","year":"2021","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib153","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000771","article-title":"What are the attributes prioritized in the choice of therapy in chronic lymphocytic leukemia? a patient-physician cross-matching analysis of a discrete choice experiment","volume":"6","author":"Laurenti","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.jval.2025.06.004_bib154","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2015.11.006","article-title":"Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: a conjoint analysis","volume":"40","author":"Landfeldt","year":"2015","journal-title":"Leuk Res"},{"issue":"24","key":"10.1016\/j.jval.2025.06.004_bib155","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2017007294","article-title":"Patients\u2019 priorities in selecting chronic lymphocytic leukemia treatments","volume":"1","author":"Mansfield","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jval.2025.06.004_bib156","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/PPA.S289139","article-title":"Oncologist and patient preferences for novel agents in first-line treatment for chronic lymphocytic leukemia: commonalities and disconnects","volume":"15","author":"Le","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib157","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1186\/s12885-024-12589-9","article-title":"Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia","volume":"24","author":"Fifer","year":"2024","journal-title":"BMC Cancer"},{"issue":"28","key":"10.1016\/j.jval.2025.06.004_bib158","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/14796694.2024.2348440","article-title":"Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment","volume":"20","author":"Ravelo","year":"2024","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3216","article-title":"Patients\u2019 preferences for chronic lymphocytic leukemia treatment: the CHOICE study","volume":"42","author":"Sportoletti","year":"2024","journal-title":"Hematol Oncol"},{"issue":"23","key":"10.1016\/j.jval.2025.06.004_bib160","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1002\/cncr.28940","article-title":"Patient preferences in advanced or recurrent ovarian cancer","volume":"120","author":"Havrilesky","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib161","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ygyno.2016.10.021","article-title":"Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy","volume":"143","author":"Lee","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.jval.2025.06.004_bib162","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1002\/cncr.32447","article-title":"Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer","volume":"125","author":"Havrilesky","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib163","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ygyno.2020.01.026","article-title":"Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment","volume":"156","author":"Havrilesky","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib164","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2021.05.022","article-title":"The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens","volume":"162","author":"Havrilesky","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib165","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fon-2021-0567","article-title":"Patients\u2019 and oncologists\u2019 preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer","volume":"18","author":"Stone","year":"2022","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib166","first-page":"219","article-title":"Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer","volume":"13","author":"Sun","year":"2005","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib167","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3111\/13696998.2012.708689","article-title":"Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma","volume":"15","author":"Wong","year":"2012","journal-title":"J Med Econ"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib168","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2165\/11593370-000000000-00000","article-title":"Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma","volume":"29","author":"Mohamed","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib169","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jval.2012.05.008","article-title":"A comparison of preferences of targeted therapy for metastatic renal cell carcinoma between the patient group and health care professional group in South Korea","volume":"15","author":"Park","year":"2012","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib170","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1080\/03007995.2016.1211521","article-title":"The effect of information on preferences for treatments of metastatic renal cell carcinoma","volume":"32","author":"Mansfield","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib171","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40273-018-0640-7","article-title":"Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: a discrete-choice experiment","volume":"36","author":"Gonzalez","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib172","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40271-023-00659-2","article-title":"Preferences and willingness to pay for medication in patients with renal cell carcinoma in China: a discrete-choice experiment","volume":"17","author":"Ding","year":"2024","journal-title":"Patient"},{"key":"10.1016\/j.jval.2025.06.004_bib173","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2147\/PPA.S460994","article-title":"Treatment preferences among patients with renal cell carcinoma: results from a discrete choice experiment","volume":"18","author":"Ornstein","year":"2024","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib174","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1055-9965.EPI-19-1277","article-title":"Age at diagnosis and patient preferences for treatment outcomes in AML: a discrete choice experiment to explore meaningful benefits","volume":"29","author":"Richardson","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jval.2025.06.004_bib175","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2147\/PPA.S442530","article-title":"Patient preferences for treatment in relapsed\/refractory acute leukemia in the United Kingdom: a discrete choice experiment","volume":"18","author":"Mott","year":"2024","journal-title":"PPA"},{"key":"10.1016\/j.jval.2025.06.004_bib176","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.2147\/PPA.S421871","article-title":"Patient and physician preferences for acute myeloid leukemia maintenance treatments following hematopoietic stem cell transplantation","volume":"17","author":"Saini","year":"2023","journal-title":"PPA"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib177","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/pon.5652","article-title":"Prioritizing the worries of AML patients: quantifying patient experience using best\u2013worst scaling","volume":"30","author":"Richardson","year":"2021","journal-title":"Psycho-Oncology"},{"issue":"32","key":"10.1016\/j.jval.2025.06.004_bib178","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.2217\/fon-2021-0697","article-title":"Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study","volume":"17","author":"Lo","year":"2021","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib179","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3390\/cancers15051470","article-title":"Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jval.2025.06.004_bib180","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/PPA.S198363","article-title":"Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments","volume":"13","author":"Chiba","year":"2019","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib181","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12885-022-10388-8","article-title":"Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study","volume":"23","author":"Parikh","year":"2023","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib182","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ejso.2020.04.014","article-title":"Importance of patient reported and clinical outcomes for patients with locally advanced rectal cancer and their treating physicians. Do clinicians know what patients want?","volume":"46","author":"van der Valk","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib183","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bjc.6603954","article-title":"Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients\u2019 and oncologists\u2019 preferences","volume":"97","author":"Pieterse","year":"2007","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.jval.2025.06.004_bib184","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/DCR.0b013e3181c001b9","article-title":"Preferences for outcomes of treatment for rectal cancer: patient and clinician utilities and their application in an interactive computer-based decision aid","volume":"52","author":"Masya","year":"2009","journal-title":"Dis Colon Rectum"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib185","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/DCR.0000000000001166","article-title":"Patient and physician preferences for nonoperative management for low rectal cancer: is it a reasonable treatment option?","volume":"61","author":"Kennedy","year":"2018","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib186","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1472-6947-13-118","article-title":"Measuring preferences for analgesic treatment for cancer pain: how do African-Americans and Whites perform on choice-based conjoint (CBC) analysis experiments?","volume":"13","author":"Meghani","year":"2013","journal-title":"BMC Med Inform Decis Mak"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib187","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40271-017-0236-x","article-title":"Patient preferences for pain management in advanced cancer: results from a discrete choice experiment","volume":"10","author":"Meads","year":"2017","journal-title":"Patient"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib188","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jpainsymman.2022.08.010","article-title":"Patient Preferences for Rescue Medications in the Treatment of Breakthrough Cancer Pain","volume":"64","author":"Wu","year":"2022","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib189","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1526-4637.2002.02045.x","article-title":"Utility assessments of opioid treatment for chronic pain","volume":"3","author":"Schmier","year":"2002","journal-title":"Pain Med"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib190","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2165\/11532240-000000000-00000","article-title":"Does the inclusion of a cost attribute result in different preferences for the surgical treatment of primary basal cell carcinoma?: a comparison of two discrete-choice experiments","volume":"28","author":"Essers","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib191","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-5945-12-19","article-title":"What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial","volume":"12","author":"Tinelli","year":"2012","journal-title":"BMC Dermatol"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib192","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2340\/00015555-2273","article-title":"Patient preferences for treatment of basal cell carcinoma: importance of cure and cosmetic outcome","volume":"96","author":"Martin","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib193","first-page":"21","article-title":"Patients\u2019 preferences for bone metastases treatments in France, Germany and the United Kingdom","volume":"23","author":"Hechmati","year":"2015","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib194","first-page":"118","article-title":"Patients\u2019 and physicians\u2019 preferences for approaches to bone metastases treatment in Turkey","volume":"25","author":"Gatta","year":"2015","journal-title":"UHOD Uluslararasi Hematol-Onkol Derg"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib195","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40271-015-0158-4","article-title":"Patient, caregiver, and nurse preferences for treatments for bone metastases from solid tumors","volume":"9","author":"Qian","year":"2016","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib196","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1017\/S0266462319000217","article-title":"Patient preferences concerning alternative treatments for neuroendocrine tumors: results of the \u201cPIANO-Study.\u201d","volume":"35","author":"M\u00fchlbacher","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"12","key":"10.1016\/j.jval.2025.06.004_bib197","first-page":"1330","article-title":"Patient-defined goals and preferences among adults with advanced neuroendocrine tumors","volume":"20","author":"Li","year":"2022","journal-title":"J Nat Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib198","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/oncolo\/oyad312","article-title":"Patient priorities concerning treatment decisions for advanced neuroendocrine tumors identified by discrete choice experiments","volume":"29","author":"Anaka","year":"2024","journal-title":"The Oncologist"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib199","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1007\/s00268-015-3148-8","article-title":"Patients\u2019 preferences for surgical management of esophageal cancer: a discrete choice experiment","volume":"39","author":"De Bekker-Grob","year":"2015","journal-title":"World J Surg"},{"issue":"12","key":"10.1016\/j.jval.2025.06.004_bib200","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/bjs.10897","article-title":"Patients\u2019 preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer","volume":"105","author":"Noordman","year":"2018","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib201","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bjs\/znab358","article-title":"Preferences for active surveillance or standard oesophagectomy: discrete-choice experiment","volume":"109","author":"Van Der Wilk","year":"2022","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib202","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/fon-2022-0767","article-title":"Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients","volume":"19","author":"Grivas","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.jval.2025.06.004_bib203","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2147\/PPA.S411751","article-title":"Patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma: a multi-country discrete choice experiment","volume":"17","author":"King-Concialdi","year":"2023","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib204","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40271-024-00709-3","article-title":"Patient preferences for first-line treatment of locally advanced or metastatic urothelial carcinoma: an application of multidimensional thresholding","volume":"18","author":"Apolo","year":"2025","journal-title":"Patient"},{"key":"10.1016\/j.jval.2025.06.004_bib205","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euros.2022.12.016","article-title":"Patient preferences for treatment of bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle-invasive bladder cancer: a cross-country choice experiment","volume":"49","author":"Collacott","year":"2023","journal-title":"Eur Uro Op Sci"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib206","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/bco2.443","article-title":"Treatment preferences of patients with muscle invasive bladder cancer: a discrete choice experiment","volume":"5","author":"Mannion","year":"2024","journal-title":"BJUI Compass"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib207","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2011.10.033","article-title":"Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment","volume":"125","author":"Einstein","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib208","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/IGC.0000000000000149","article-title":"Patient preferences for side effects associated with cervical cancer treatment","volume":"24","author":"Sun","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib209","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1245\/s10434-016-5729-7","article-title":"Treatment preferences for routine lymphadenectomy versus no lymphadenectomy in early-stage endometrial cancer","volume":"24","author":"Lee","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib210","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/bjc.2016.323","article-title":"Patients\u2019 and clinicians\u2019 preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial","volume":"115","author":"Blinman","year":"2016","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib211","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jval.2014.01.002","article-title":"Discrete choice experiment to estimate breast cancer patients\u2019 preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors","volume":"17","author":"Johnson","year":"2014","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib212","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jclinepi.2011.11.008","article-title":"Discrete choice experiment produced estimates of acceptable risks of therapeutic options in cancer patients with febrile neutropenia","volume":"65","author":"Sung","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib213","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/bmt.2010.225","article-title":"Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment","volume":"46","author":"Shafey","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jval.2025.06.004_bib214","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70177","article-title":"Preferences of patients and physicians in the United States for relapsed\/refractory follicular lymphoma treatments","volume":"13","author":"Thomas","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib215","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12885-016-2975-9","article-title":"Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany","volume":"16","author":"Hofheinz","year":"2016","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib216","first-page":"7447","article-title":"Preferences for oral nutritional supplement therapy among postoperative patients with gastric cancer: a discrete choice experiment","volume":"30","author":"Wang","year":"2022","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib217","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.15566","article-title":"Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom","volume":"184","author":"Br\u00f6ckelmann","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib218","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1080\/10428194.2020.1783443","article-title":"Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment","volume":"61","author":"Khan","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2025.06.004_bib219","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/438235","article-title":"Patient benefit-risk tradeoffs for radioactive iodine-refractory differentiated thyroid cancer treatments","volume":"2015","author":"Mohamed","year":"2015","journal-title":"J Thyroid Res"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib220","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/thy.2019.0590","article-title":"Patient preferences around extent of surgery in low-risk thyroid cancer: a discrete choice experiment","volume":"30","author":"Ahmadi","year":"2020","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib221","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.hpb.2019.06.015","article-title":"Patients\u2019 treatment preferences for potentially resectable tumors of the head of the pancreas","volume":"22","author":"Molinari","year":"2020","journal-title":"HPB"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib222","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/CJI.0000000000000158","article-title":"Treatment of cervical intraepithelial neoplasia: patients preferences for surgery or immunotherapy with imiquimod","volume":"40","author":"Koeneman","year":"2017","journal-title":"J Immunother"},{"issue":"25","key":"10.1016\/j.jval.2025.06.004_bib223","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2217\/fon-2022-0421","article-title":"Patient preferences for treatment in relapsed\/refractory diffuse large B-cell lymphoma: a discrete choice experiment","volume":"18","author":"Birch","year":"2022","journal-title":"Future Oncol"},{"issue":"16","key":"10.1016\/j.jval.2025.06.004_bib224","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.3390\/cancers13163962","article-title":"Preferences of treatment strategies among women with low-risk DCIS and oncologists","volume":"13","author":"Byng","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jval.2025.06.004_bib225","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/PPA.S20445","article-title":"Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST)","volume":"5","author":"Hauber","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2025.06.004_bib226","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.oraloncology.2019.05.016","article-title":"Priorities of human papillomavirus-associated oropharyngeal cancer patients at diagnosis and after treatment","volume":"95","author":"Windon","year":"2019","journal-title":"Oral Oncol"},{"issue":"17","key":"10.1016\/j.jval.2025.06.004_bib227","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2217\/fon-2022-0082","article-title":"Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment","volume":"18","author":"Ashaye","year":"2022","journal-title":"Future Oncol"},{"issue":"13","key":"10.1016\/j.jval.2025.06.004_bib228","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2217\/fon-2020-0018","article-title":"Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany","volume":"16","author":"Eriksson","year":"2020","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib229","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1016\/j.clml.2022.04.023","article-title":"Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib230","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2247105","article-title":"Patients\u2019 willingness to accept adverse event and cost tradeoffs from oral nicotinamide for reduced risk of non-melanoma skin cancer","volume":"34","author":"Boeri","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib231","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40271-019-00355-0","article-title":"Patient and oncologist preferences for the treatment of adults with advanced soft tissue sarcoma: a discrete choice experiment","volume":"12","author":"Ivanova","year":"2019","journal-title":"Patient"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib232","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MAO.0b013e3181cc06cb","article-title":"Mapping clinical outcomes expectations to treatment decisions: an application to vestibular schwannoma management","volume":"31","author":"Cheung","year":"2010","journal-title":"Otol Neurotol"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib233","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1002\/cam4.5080","article-title":"Patient preferences regarding treatment options for Waldenstr\u00f6m\u2019s macroglobulinemia: a discrete choice experiment","volume":"12","author":"Amaador","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jval.2025.06.004_bib234","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/PPA.S14217","article-title":"A discrete choice experiment evaluation of patients\u2019 preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management","volume":"4","author":"Guimar\u00e3es","year":"2010","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib235","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-010942","article-title":"Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey","volume":"8","author":"Liu","year":"2023","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.jval.2025.06.004_bib236","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2147\/PPA.S401465","article-title":"The impact of substantial improvements in HbA1c and weight loss on the medication preferences of people with type 2 diabetes","volume":"17","author":"Gelhorn","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2025.06.004_bib237","article-title":"Patient preferences for diabetes treatment among people with type 2 diabetes mellitus in China: a discrete choice experiment","volume":"9","author":"Huang","year":"2021","journal-title":"Front Public Health"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib238","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1524-4733.2004.74007.x","article-title":"Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30\/70: a multicountry application of a discrete choice experiment","volume":"7","author":"Aristides","year":"2004","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib239","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1464-5491.2009.02696.x","article-title":"Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents","volume":"26","author":"Hauber","year":"2009","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib240","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1185\/03007991003657867","article-title":"Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes","volume":"26","author":"Jendle","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib241","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3111\/13696998.2010.529377","article-title":"A comparison of preferences for two GLP-1 products-liraglutide and exenatide-for the treatment of type 2 diabetes","volume":"13","author":"Polster","year":"2010","journal-title":"J Med Econ"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib242","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1742-1241.2010.02590.x","article-title":"A quantitative assessment of patient barriers to insulin","volume":"65","author":"Casciano","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib243","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.clinthera.2011.07.017","article-title":"Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus","volume":"33","author":"Lloyd","year":"2011","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib244","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1185\/03007995.2011.625404","article-title":"Patient preferences for diabetes management among people with type 2 diabetes in Denmark a discrete choice experiment","volume":"27","author":"B\u00f8gelund","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib245","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/dom.12091","article-title":"Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK","volume":"15","author":"Gelhorn","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jval.2025.06.004_bib246","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2147\/PPA.S43465","article-title":"Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes","volume":"7","author":"Hauber","year":"2013","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib247","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.diabet.2013.06.001","article-title":"Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences","volume":"39","author":"Mohamed","year":"2013","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib248","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s13300-015-0094-2","article-title":"A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus","volume":"6","author":"Hauber","year":"2015","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jval.2025.06.004_bib249","first-page":"1443","article-title":"Patients\u2019 and physicians\u2019 preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment","volume":"9","author":"Morillas","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2025.06.004_bib250","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2147\/PPA.S90842","article-title":"Evaluating preferences for profiles of GLP-1 receptor agonists among injection-na\u00efve type 2 diabetes patients in the UK","volume":"9","author":"Gelhorn","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib251","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1185\/03007995.2015.1117433","article-title":"A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes","volume":"32","author":"Hauber","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib252","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2016-000192","article-title":"Patients\u2019 with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes","volume":"4","author":"Feher","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jval.2025.06.004_bib253","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2147\/PPA.S109289","article-title":"Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan","volume":"10","author":"Gelhorn","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib254","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10198-015-0750-5","article-title":"What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences","volume":"17","author":"M\u00fchlbacher","year":"2016","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib255","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jval.2016.11.023","article-title":"Be careful what you ask for: effects of benefit descriptions on diabetes patients\u2019 benefit-risk tradeoff preferences","volume":"20","author":"von Arx","year":"2017","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib256","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13300-017-0230-2","article-title":"Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-na\u00efve patients with type 2 diabetes mellitus: a multinational preference study","volume":"8","author":"Qin","year":"2017","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib257","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13300-017-0237-8","article-title":"Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-experienced patients with type 2 diabetes mellitus: a preference study in Germany and the United Kingdom","volume":"8","author":"Qin","year":"2017","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib258","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s13300-017-0326-8","article-title":"Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey","volume":"8","author":"Mansfield","year":"2017","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib259","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s12913-018-3484-0","article-title":"Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment","volume":"18","author":"Fifer","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jval.2025.06.004_bib260","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jocm.2018.11.002","article-title":"Explore preference heterogeneity for treatment among people with Type 2 diabetestype 2 diabetes: a comparison of random-parameters and latent-class estimation techniques","volume":"30","author":"Zhou","year":"2019","journal-title":"J Choice Mode"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib261","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00592-018-1236-6","article-title":"Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis","volume":"56","author":"Marchesini","year":"2019","journal-title":"Acta Diabetol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib262","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13300-019-0591-9","article-title":"Patient Preferences for GLP-1 receptor agonist treatment of type 2 diabetes mellitus in Japan: a discrete choice experiment","volume":"10","author":"Brooks","year":"2019","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib263","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcjd.2019.04.014","article-title":"Capturing adult patient preferences toward benefits and risks of second-line antihyperglycemic medications used in type 2 diabetes: a discrete choice experiment","volume":"44","author":"Donnan","year":"2020","journal-title":"Can J Diabetes"},{"issue":"7","key":"10.1016\/j.jval.2025.06.004_bib264","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jval.2020.01.023","article-title":"Patient preferences for medications in managing type 2 diabetes mellitus: a discrete choice experiment","volume":"23","author":"Ozdemir","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib265","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12325-020-01561-1","article-title":"Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment","volume":"38","author":"Igarashi","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jval.2025.06.004_bib266","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.617409","article-title":"Differences in importance attached to drug effects between patients with type 2 diabetes from the Netherlands and Turkey: a preference study","volume":"11","author":"Roldan Munoz","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib267","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10198-021-01264-6","article-title":"Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment","volume":"22","author":"M\u00fchlbacher","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib268","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s41669-020-00246-3","article-title":"Understanding patients\u2019 willingness to pay for biphasic insulin aspart 30\/70 in a pen device for type 2 diabetes treatment in an out-of-pocket payment market","volume":"5","author":"Murthy","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.jval.2025.06.004_bib269","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/PPA.S367985","article-title":"Preferences for patients with type 2 diabetes mellitus for medications in Shandong province, China: a discrete choice experiment","volume":"16","author":"Lv","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2025.06.004_bib270","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.2147\/PPA.S391719","article-title":"Patients\u2019 preferences for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"16","author":"Banjara","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib271","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40200-021-00962-5","article-title":"Patient preferences for the treatment of type 2 diabetes in Australia: a discrete choice experiment","volume":"21","author":"Ahmad","year":"2022","journal-title":"J Diabetes Metab Disord"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib272","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1007\/s12325-022-02181-7","article-title":"Preference for type 2 diabetes therapies in the United States: a discrete choice experiment","volume":"39","author":"Shubrook","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib273","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1186\/s12889-022-14244-z","article-title":"Investigating patients\u2019 preferences for new anti-diabetic drugs to inform public health insurance coverage decisions: a discrete choice experiment in China","volume":"22","author":"Geng","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jval.2025.06.004_bib274","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijcard.2022.09.009","article-title":"Patient preferences for newer oral therapies in type 2 diabetes","volume":"371","author":"Savarese","year":"2023","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib275","first-page":"139","article-title":"Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment","volume":"29","author":"Panchal","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib276","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40271-024-00694-7","article-title":"Evaluating the preferences and willingness-to-pay for oral antidiabetic drugs among patients with type 2 diabetes mellitus in China: a discrete choice experiment","volume":"17","author":"Chuang","year":"2024","journal-title":"Patient"},{"key":"10.1016\/j.jval.2025.06.004_bib277","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/2552658","article-title":"Evaluating preferences of hospitalized diabetes patients for hospital-wide glycemic control programme: a discrete choice experiment","volume":"2024","author":"Dai","year":"2024","journal-title":"J Diabetes Res"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib278","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1007\/s13300-024-01652-0","article-title":"Perspectives and preferences of people with type 2 diabetes for the attributes of weekly insulin","volume":"15","author":"Gelsey","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jval.2025.06.004_bib279","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1413642","article-title":"Eliciting medication preferences of patients with type 2 diabetes under different insurance coverages in China","volume":"12","author":"Zheng","year":"2024","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib280","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s13300-018-0391-7","article-title":"Changing patients\u2019 treatment preferences and values with a decision aid for type 2 diabetes mellitus: results from the treatment arm of a randomized controlled trial","volume":"9","author":"Bailey","year":"2018","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib281","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/03007995.2016.1253553","article-title":"Patient preferences for diabetes treatment attributes and drug classes","volume":"33","author":"Flood","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.jval.2025.06.004_bib282","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1001\/jamainternmed.2019.3806","article-title":"Patient perceptions of diabetes guideline frameworks for individualizing glycemic targets","volume":"179","author":"Schoenborn","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib283","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40271-020-00450-7","article-title":"Comparing the preferences of patients and the general public for treatment outcomes in type 2 diabetes mellitus","volume":"14","author":"Crossnohere","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.jval.2025.06.004_bib284","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.802897","article-title":"What is valued most by patients with type 2 diabetes mellitus when selecting second-line antihyperglycemic medications in China","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2025.06.004_bib285","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2147\/PPA.S355638","article-title":"Patients\u2019 preference between dpp4i and sglt2i for type 2 diabetes treatment: a cross-sectional evaluation","volume":"16","author":"Costa Gil","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib286","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1089\/dia.2019.0444","article-title":"Parent preferences for delaying insulin dependence in children at risk of stage III type 1 diabetes","volume":"22","author":"DiSantostefano","year":"2020","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib287","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/dme.13592","article-title":"Preferences for treatment among adolescents with type 1 diabetes: a national study using a discrete choice experiment model","volume":"35","author":"Forsander","year":"2018","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib288","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/dia.2019.0027","article-title":"Adjunct therapy in type 1 diabetes: a survey to uncover unmet needs and patient preferences beyond HbA1c measures","volume":"21","author":"Pettus","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib289","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.2337\/dc19-0548","article-title":"Exploring patient preferences for adjunct-to-insulin therapy in type 1 diabetes","volume":"42","author":"Perkins","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jval.2025.06.004_bib290","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/PPA.S262358","article-title":"Preferences for outcomes among adults with type 1 diabetes and caregivers of children with type 1 diabetes","volume":"14","author":"Marinac","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib291","doi-asserted-by":"crossref","first-page":"E368","DOI":"10.1097\/TP.0000000000004189","article-title":"Preferences for risks and benefits of islet cell transplantation for persons with type 1 diabetes with history of episodes of severe hypoglycemia: a discrete-choice experiment to inform regulatory decisions","volume":"106","author":"Wilson","year":"2022","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib292","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1007\/s00464-014-4044-2","article-title":"Incorporating patient-preference evidence into regulatory decision making","volume":"29","author":"Ho","year":"2015","journal-title":"Surg Endosc"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib293","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.4375","article-title":"Patient preferences for bariatric surgery: findings from a survey using discrete choice experiment methodology","volume":"154","author":"Rozier","year":"2019","journal-title":"JAMA Surg"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib294","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40258-020-00554-z","article-title":"Preferences for weight loss treatment amongst treatment-seeking patients with severe obesity: a discrete choice experiment","volume":"18","author":"Queally","year":"2020","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib295","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11102-018-00933-9","article-title":"AcroVoice: eliciting the patients\u2019 perspective on acromegaly disease activity","volume":"22","author":"Jackson","year":"2019","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib296","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12020-023-03462-z","article-title":"Preference of acromegaly patients for treatment attributes in Spain","volume":"82","author":"Fajardo","year":"2023","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib297","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s13300-021-01178-9","article-title":"Patient preferences for pharmacological diabetes treatment among people with diabetes in Spain: a discrete choice experiment","volume":"13","author":"G\u00f3mez-Peralta","year":"2022","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib298","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1177\/19322968221095882","article-title":"People with diabetes and caregivers prefer rescue glucagon treatment with a wider storage temperature range and a nasal administration, when efficacy is similar: a discrete choice experiment in Spain","volume":"17","author":"Mitchell","year":"2023","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib299","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13023-024-03371-y","article-title":"Different diseases, different needs: patient preferences for gene therapy in lysosomal storage disorders, a probabilistic threshold technique survey","volume":"19","author":"Corazolla","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12882-017-0665-8","article-title":"Hemodialysis patients\u2019 preferences for the management of secondary hyperparathyroidism","volume":"18","author":"Hauber","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jval.2025.06.004_bib301","article-title":"A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: a study of patients\u2019 preferences","volume":"21","author":"Bhashyam","year":"2019","journal-title":"Mol Genet Metab Rep"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib302","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1089\/thy.2019.0821","article-title":"The influence of cosmetic concerns on patient preferences for approaches to thyroid lobectomy: a discrete choice experiment","volume":"30","author":"Sukpanich","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib303","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.2196\/ijmr.3776","article-title":"Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients","volume":"4","author":"Wicks","year":"2015","journal-title":"Interact J Med Res"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib304","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00415-009-0084-2","article-title":"Multiple sclerosis patients\u2032\u2019 benefit-risk preferences: Serious adverse event serious adverse event risks versus treatment efficacy","volume":"256","author":"Johnson","year":"2009","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib305","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3111\/13696998.2013.811079","article-title":"A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis","volume":"16","author":"Shingler","year":"2013","journal-title":"J Med Econ"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib306","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1756285614555335","article-title":"Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis","volume":"7","author":"Utz","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"issue":"1-2","key":"10.1016\/j.jval.2025.06.004_bib307","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2014.06.030","article-title":"Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices","volume":"344","author":"Wilson","year":"2014","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib308","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1756285615622736","article-title":"A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany","volume":"9","author":"Poulos","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib309","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40271-015-0136-x","article-title":"Patient preferences for injectable treatments for multiple sclerosis in the united states: a discrete-choice experiment","volume":"9","author":"Poulos","year":"2016","journal-title":"Patient"},{"key":"10.1016\/j.jval.2025.06.004_bib310","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2147\/PPA.S114619","article-title":"Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment","volume":"10","author":"Garcia-Dominguez","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib311","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7224\/1537-2073.2016-039","article-title":"Preferences for multiple sclerosis treatments: using a discrete-choice experiment to examine differences across subgroups of US patients","volume":"19","author":"Mansfield","year":"2017","journal-title":"Int J MS Care"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib312","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1017\/S0266462318000491","article-title":"Preferences of patients with multiple sclerosis for attributes of injectable multiple sclerosis treatments in the United Kingdom and France","volume":"34","author":"Poulos","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"issue":"12","key":"10.1016\/j.jval.2025.06.004_bib313","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/tmi.13157","article-title":"A new approach to pharmaceutical pricing based on patients\u2019 willingness to pay","volume":"23","author":"Rahimi","year":"2018","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jval.2025.06.004_bib314","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2019.07.005","article-title":"Patients\u2019 preferences and willingness-to-pay for disease-modifying therapies","volume":"35","author":"Frost","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib315","article-title":"Patient and physician preferences for multiple sclerosis treatments in Germany: a discrete-choice experiment study","volume":"6","author":"Poulos","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib316","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0272989X19897944","article-title":"Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options","volume":"40","author":"Jonker","year":"2020","journal-title":"Med Decis Mak"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib317","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40271-020-00429-4","article-title":"The impact of reproductive issues on preferences of women with relapsing multiple sclerosis for disease-modifying treatments","volume":"13","author":"Webb","year":"2020","journal-title":"Patient"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib318","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/03007995.2021.1940911","article-title":"Patient and neurologist preferences in the UK for relapsing\u2013remitting multiple sclerosis treatments: findings from a discrete choice experiment","volume":"37","author":"Tencer","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2025.06.004_bib319","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/PPA.S306498","article-title":"Patient and neurologist preferences in the united states for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment","volume":"15","author":"Kumar","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib320","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/0272989X20979833","article-title":"Is easier better than harder? an experiment on choice experiments for benefit-risk tradeoff preferences","volume":"41","author":"Yang","year":"2021","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.jval.2025.06.004_bib321","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117587","article-title":"An implantable device to treat multiple sclerosis: a discrete choice experiment on patient preferences in three European countries","volume":"428","author":"Visser","year":"2021","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib322","article-title":"Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: a discrete choice experiment","volume":"9","author":"Tervonen","year":"2023","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib323","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00415-024-12725-2","article-title":"Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals","volume":"272","author":"Gasperini","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.jval.2025.06.004_bib324","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vhri.2022.04.001","article-title":"Preferences for disease-modifying therapies in Argentina: cross-sectional conjoint analysis of patients and neurologists","volume":"31","author":"Rojas","year":"2022","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7224\/1537-2073.2013-053","article-title":"Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis","volume":"17","author":"Wilson","year":"2015","journal-title":"Int J MS Care"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib326","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1756285616648060","article-title":"Quantitative analysis of multiple sclerosis patients\u2019 preferences for drug treatment: a best-worst scaling study","volume":"9","author":"Lynd","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib327","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164862","article-title":"Identification and prioritization of important attributes of disease-modifying drugs in decision making among patients with multiple sclerosis: a nominal group technique and best-worst scaling","volume":"11","author":"Kremer","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib328","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014433","article-title":"Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study","volume":"7","author":"Arroyo","year":"2017","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib329","first-page":"822","article-title":"Factors associated with patient preferences for disease-modifying therapies in multiple sclerosis","volume":"23","author":"Hincapie","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib330","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/13696998.2017.1336099","article-title":"A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis","volume":"20","author":"Bottomley","year":"2017","journal-title":"J Med Econ"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib331","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s11136-015-1187-0","article-title":"Health-related quality of life in Parkinson\u2019s: impact of \u2018off\u2019 time and stated treatment preferences","volume":"25","author":"Kerr","year":"2016","journal-title":"Qual Life Res"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib332","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jval.2017.06.001","article-title":"Patient preferences for device-aided treatments indicated for advanced Parkinson disease","volume":"20","author":"Marshall","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2025.06.004_bib333","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2147\/PPA.S301644","article-title":"Patient preferences for treating \u201coff\u201d episodes in Parkinson\u2019s disease: a discrete choice experiment","volume":"15","author":"Thach","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib334","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12910-023-00966-1","article-title":"Patients accept therapy using embryonic stem cells for Parkinson\u2019s disease: a discrete choice experiment","volume":"24","author":"Bywall","year":"2023","journal-title":"BMC Med Ethics"},{"key":"10.1016\/j.jval.2025.06.004_bib335","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2147\/PPA.S420051","article-title":"Patient\u2019 preferences for adjunctive Parkinson\u2019s disease treatments: a discrete-choice experiment","volume":"17","author":"Serbin","year":"2023","journal-title":"PPA"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib336","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jphys.2020.12.007","article-title":"People with Parkinson\u2019s disease are more willing to do additional exercise if the exercise program has specific attributes: a discrete choice experiment","volume":"67","author":"Paul","year":"2021","journal-title":"J Physiother"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib337","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160771","article-title":"Involving patients in weighting benefits and harms of treatment in Parkinson\u2019s disease","volume":"11","author":"Weernink","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib338","article-title":"Parkinson\u2019s patients\u2019 tolerance for risk and willingness to wait for potential benefits of novel neurostimulation devices: a patient-centered threshold technique study","volume":"6","author":"Hauber","year":"2021","journal-title":"MDM Policy Pract"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib339","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.yebeh.2012.05.020","article-title":"Patients\u2019 preferences for treatment outcomes of add-on antiepileptic drugs: a conjoint analysis","volume":"24","author":"Manjunath","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.jval.2025.06.004_bib340","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.yebeh.2018.01.025","article-title":"Patient versus neurologist preferences: a discrete choice experiment for antiepileptic drug therapies","volume":"80","author":"Ettinger","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib341","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/cpt.1231","article-title":"Patient-focused drug development methods for benefit\u2013risk assessments: a case study using a discrete choice experiment for antiepileptic drugs","volume":"105","author":"Holmes","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2025.06.004_bib342","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.602481","article-title":"Patient preference for antiepileptic drugs treatment in China: evidence from the discrete choice experiment","volume":"11","author":"Hua","year":"2020","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib343","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/epi.17137","article-title":"Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: discrete choice experiment eliciting preferences in real-world study \u201cVOTE.\u201d","volume":"63","author":"Rosenow","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.jval.2025.06.004_bib344","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108529","article-title":"Patient preferences pertaining to treatment options for drug-resistant focal epilepsy","volume":"127","author":"Sinha","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib345","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/head.12142","article-title":"Evaluating migraineurs\u2019 preferences for migraine treatment outcomes using a choice experiment","volume":"53","author":"Gonzalez","year":"2013","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib346","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.3390\/ijerph18094916","article-title":"Investigating patients\u2019 preferences to inform drug development decisions: novel insights from a discrete choice experiment in migraine","volume":"18","author":"Torbica","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib347","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40120-024-00663-0","article-title":"A discrete-choice experiment assessing the patient preferences and real-world experiences of patients with migraine in Japan","volume":"13","author":"Takeshima","year":"2024","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib348","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12883-021-02220-w","article-title":"Patients and general practitioners assessment of the main outcomes employed in the acute and preventive treatment of migraine: a cross sectional study","volume":"21","author":"Trigo-L\u00f3pez","year":"2021","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib349","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1468-2982.2005.00797.x","article-title":"An assessment of the burden of migraine using the willingness to pay model","volume":"25","author":"Hamelsky","year":"2005","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib350","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-020-01667-3","article-title":"Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment","volume":"16","author":"Monnette","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"suppl 1","key":"10.1016\/j.jval.2025.06.004_bib351","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40273-021-01092-9","article-title":"Preferences and utilities for treatment attributes in type 2 and non-ambulatory type 3 spinal muscular atrophy in the United Kingdom","volume":"40","author":"Lo","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"suppl 1","key":"10.1016\/j.jval.2025.06.004_bib352","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40273-021-01118-2","article-title":"Patient and caregiver treatment preferences in type 2 and non-ambulatory type 3 spinal muscular atrophy: a discrete choice experiment survey in five European countries","volume":"40","author":"Lo","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib353","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/dmcn.15135","article-title":"Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: a discrete choice experiment","volume":"64","author":"Carey","year":"2022","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib354","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309666","article-title":"Treatment preferences in spinal muscular atrophy: a swing weighting study for caregivers of patients with SMA types 1 and 2","volume":"19","author":"Patel","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib355","first-page":"42","article-title":"A discrete choice experiment to elicit patient willingness to pay for attributes of treatment-induced symptom relief in comorbid insomnia","volume":"24","author":"Roy","year":"2015","journal-title":"Manag Care"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib356","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40271-018-0303-y","article-title":"Patient Preferences for managing insomnia: a discrete choice experiment","volume":"11","author":"Cheung","year":"2018","journal-title":"Patient"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib357","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsac204","article-title":"Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trials","volume":"45","author":"Heidenreich","year":"2022","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib358","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40271-022-00574-y","article-title":"A comparison of caregiver and patient preferences for treating Duchenne muscular dystrophy","volume":"15","author":"Crossnohere","year":"2022","journal-title":"Patient"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib359","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1664","article-title":"Patients\u2019 and caregivers\u2019 maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy","volume":"9","author":"Peay","year":"2021","journal-title":"Mol Genet Genomic Med"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib360","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s11136-018-1891-7","article-title":"Engaging patients and caregivers in prioritizing symptoms impacting quality of life for Duchenne and Becker muscular dystrophy","volume":"27","author":"Hollin","year":"2018","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib361","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/mus.25411","article-title":"Patient-centered benefit-risk assessment in Duchenne muscular dystrophy","volume":"55","author":"Hollin","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib362","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40271-014-0104-x","article-title":"Caregiver Preferences for Emerging Duchenne Muscular Dystrophy Treatments: a Comparison of Best-Worst Scaling and Conjoint Analysis","volume":"8","author":"Hollin","year":"2015","journal-title":"Patient"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib363","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40271-023-00665-4","article-title":"Preferences of patients with amyotrophic lateral sclerosis for intrathecal drug delivery: choosing between an implanted drug-delivery device and therapeutic lumbar puncture","volume":"17","author":"Seo","year":"2024","journal-title":"Patient"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib364","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/jnnp-2021-328194","article-title":"Composite endpoint for ALS clinical trials based on patient preference: patient-ranked order of function (PROOF)","volume":"93","author":"van Eijk","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib365","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s41687-024-00810-z","article-title":"Treatment decision-making factors among patients with cervical myelopathy: a discrete-choice experiment","volume":"8","author":"Sarraj","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib366","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1017\/S1041610217000485","article-title":"Pharmacological and non-pharmacological treatment preferences of healthcare professionals and proxies for challenging behaviors in patients with dementia","volume":"29","author":"Janus","year":"2017","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib367","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s13023-024-03408-2","article-title":"Preferences for genetic interventions for SCA and Huntington\u2019s disease: results of a discrete choice experiment among patients","volume":"19","author":"van Os","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib368","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3171\/2020.5.PEDS2095","article-title":"Patient and parental assessment of factors influencing the choice of treatment in pediatric hydrocephalus","volume":"26","author":"Tamber","year":"2020","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.jval.2025.06.004_bib369","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2147\/PPA.S353412","article-title":"Preferences for attributes of sodium oxybate treatment: a discrete choice experiment in patients with narcolepsy","volume":"16","author":"Dubow","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib370","first-page":"239","article-title":"Comparing outcomes of a discrete choice experiment and case 2 best-worst scaling: an application to neuromuscular disease treatment","volume":"16","author":"Soekhai","year":"2023","journal-title":"Patient"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib371","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/papr.12989","article-title":"Oral or topical pain therapy\u2014how would patients decide? a discrete choice experiment in patients with peripheral neuropathic pain","volume":"21","author":"Schubert","year":"2021","journal-title":"Pain Pract"},{"key":"10.1016\/j.jval.2025.06.004_bib372","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41394-019-0213-9","article-title":"Risk-benefit value of upper extremity function by an implanted electrical stimulation device targeting chronic cervical spinal cord injury","volume":"5","author":"Anderson","year":"2019","journal-title":"Spinal Cord Ser Cases"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib373","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1682\/JRRD.2004.07.0088","article-title":"A multicriteria decision analysis of augmentative treatment of upper limbs in persons with tetraplegia","volume":"42","author":"Hummel","year":"2005","journal-title":"J Rehabil Res Dev"},{"key":"10.1016\/j.jval.2025.06.004_bib374","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.668880","article-title":"What tinnitus therapy outcome measures are important for patients?\u2013a discrete choice experiment","volume":"12","author":"Rademaker","year":"2021","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib375","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40273-013-0126-6","article-title":"Eliciting preferences to inform patient-centred policies: the case of psoriasis","volume":"32","author":"Torbica","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib376","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12592","article-title":"Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis)","volume":"31","author":"Rigopoulos","year":"2018","journal-title":"Dermatol Ther"},{"issue":"9","key":"10.1016\/j.jval.2025.06.004_bib377","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/archderm.143.9.1175","article-title":"Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis","volume":"143","author":"Seston","year":"2007","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib378","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/09546634.2011.588193","article-title":"The value to patients of reducing lesion severity in plaque psoriasis","volume":"22","author":"Hauber","year":"2011","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib379","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjd.14798","article-title":"Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment","volume":"176","author":"Gonzalez","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jval.2025.06.004_bib380","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/PPA.S152509","article-title":"Measuring the importance of health domains in psoriasis \u2013 discrete choice experiment versus rating scales","volume":"12","author":"Gutknecht","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib381","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1080\/09546634.2020.1839007","article-title":"Exploring determinants of psoriasis patients\u2019 treatment choices: a discrete-choice experiment study in the United States and Germany","volume":"33","author":"Feldman","year":"2022","journal-title":"J Dermatol Treat"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib382","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/hec.1117","article-title":"Ordering effect and price sensitivity in discrete choice experiments: need we worry?","volume":"15","author":"Kj\u00e6r","year":"2006","journal-title":"Health Econ"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib383","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archdermatol.2011.309","article-title":"Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes","volume":"147","author":"Schaarschmidt","year":"2011","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib384","first-page":"189","article-title":"Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability","volume":"15","author":"Kromer","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib385","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/09546634.2015.1034071","article-title":"Psoriasis patients\u2019 willingness to accept side-effect risks for improved treatment efficacy","volume":"26","author":"Kauf","year":"2015","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jval.2025.06.004_bib386","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PPA.S121838","article-title":"Evaluation of psoriasis patients\u2019 attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments","volume":"11","author":"Eliasson","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib387","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/09546634.2017.1329499","article-title":"What is clearance worth? Patients\u2019 stated risk tolerance for psoriasis treatments","volume":"28","author":"Fairchild","year":"2017","journal-title":"J Dermatol Treat"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib388","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s13555-017-0205-2","article-title":"Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis","volume":"7","author":"Alcusky","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib389","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2340\/00015555-2834","article-title":"Patients\u2019 and physicians\u2019 preferences for systemic psoriasis treatments: a nationwide comparative discrete choice experiment (PsoCompare)","volume":"98","author":"Schaarschmidt","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib390","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s41669-018-0104-1","article-title":"Patient and physician preferences for therapy characteristics for psoriasis: a discrete choice experiment in Japan","volume":"3","author":"Bolt","year":"2019","journal-title":"Pharmacoecon Open"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib391","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/1346-8138.14870","article-title":"Patient preference for biologic treatments of psoriasis in Japan","volume":"46","author":"Tada","year":"2019","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib392","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1080\/09546634.2020.1869145","article-title":"Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: results from a discrete-choice experiment in a multicountry study","volume":"33","author":"Boeri","year":"2022","journal-title":"J Dermatol Treat"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib393","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1080\/09546634.2022.2059052","article-title":"Patient preferences for topical psoriasis treatments: a discrete choice experiment","volume":"33","author":"Hoelker","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jval.2025.06.004_bib394","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2147\/PPA.S357795","article-title":"Patient preference for biologic treatments of psoriasis in the Chinese setting","volume":"16","author":"Lang","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib395","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1346-8138.16703","article-title":"Psoriasis patient preferences for the use of biologics during the coronavirus era","volume":"50","author":"Tada","year":"2023","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jval.2025.06.004_bib396","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/1346-8138.16746","article-title":"A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan","volume":"50","author":"Komine","year":"2023","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib397","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13555-024-01159-3","article-title":"Unmet needs and treatment preference of systemic treatments for moderate-to-severe psoriasis from the perspectives of patients and dermatologists in China","volume":"14","author":"Kuang","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib398","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2339440","article-title":"Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia","volume":"35","author":"Smith","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib399","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s13555-019-00334-1","article-title":"Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey","volume":"9","author":"Gorelick","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib400","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09546634.2016.1177161","article-title":"Benefit-risk tradeoff preferences for chronic hand eczema treatments","volume":"28","author":"Hauber","year":"2017","journal-title":"J Dermatol Treat"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib401","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/09546634.2019.1623860","article-title":"Patient and physician preferences for atopic dermatitis injection treatments in Japan","volume":"31","author":"Okubo","year":"2020","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib402","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1080\/09546634.2020.1832185","article-title":"Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment","volume":"33","author":"Boeri","year":"2022","journal-title":"J Dermatol Treat"},{"issue":"8","key":"10.1016\/j.jval.2025.06.004_bib403","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058799","article-title":"Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment","volume":"12","author":"Thomas","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2025.06.004_bib404","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.24339","article-title":"Patient preferences in the treatment of moderate-to-severe atopic dermatitis","volume":"104","author":"Ameen","year":"2024","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib405","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2417966","article-title":"Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany","volume":"35","author":"Durno","year":"2024","journal-title":"J Dermatol Treat"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib406","article-title":"Adult, adolescent, and caregiver preferences for attributes of topical treatments for mild-to-moderate atopic dermatitis: a discrete-choice experiment","volume":"35","author":"Feldman","year":"2024","journal-title":"J Dermatol Treat"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib407","article-title":"Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment","volume":"35","author":"Feldman","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib408","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2308682","article-title":"Patients\u2019 preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most","volume":"35","author":"Schaarschmidt","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib409","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2222201","article-title":"Patient preferences for atopic dermatitis treatments: a discrete choice experiment","volume":"34","author":"Kwatra","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib410","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2215356","article-title":"Treatment preferences among patients with mild-to-moderate atopic dermatitis","volume":"34","author":"Myers","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jval.2025.06.004_bib411","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/13696998.2023.2194804","article-title":"A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States","volume":"26","author":"Willems","year":"2023","journal-title":"J Med Econ"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib412","first-page":"1441","article-title":"Patient preferences in hidradenitis suppurativa (APProach-HS): a discrete choice experiment","volume":"20","author":"Faverio","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib413","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40271-022-00614-7","article-title":"Patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in Europe","volume":"16","author":"Willems","year":"2023","journal-title":"Patient"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib414","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.16801","article-title":"Patient preferences for topical treatment of actinic keratoses: a discrete-choice experiment","volume":"180","author":"Kopasker","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib415","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1346-8138.17056","article-title":"Treatment preferences of adults and adolescents with alopecia areata: a discrete choice experiment","volume":"51","author":"Tervonen","year":"2024","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jval.2025.06.004_bib416","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1684\/ejd.2020.3763","article-title":"Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria","volume":"30","author":"Sommer","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib417","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ecolecon.2006.06.015","article-title":"Using meta-analysis for benefits transfer: theory and practice","volume":"60","author":"Bergstrom","year":"2006","journal-title":"Ecol Econ"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib418","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1029\/2000WR900006","article-title":"Using meta-analysis for benefit transfer: in-sample convergent validity tests of an outdoor recreation database","volume":"36","author":"Rosenberger","year":"2000","journal-title":"Water Resour Res"},{"issue":"10","key":"10.1016\/j.jval.2025.06.004_bib419","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40273-024-01431-6","article-title":"A reporting checklist for discrete choice experiments in health: the DIRECT checklist","volume":"42","author":"Ride","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2025.06.004_bib420","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1467-8276.2009.01343.x","article-title":"Necessary Conditions for Valid Benefit Transfers","volume":"91","author":"Boyle","year":"2009","journal-title":"Am J Agric Econ"},{"issue":"2-3","key":"10.1016\/j.jval.2025.06.004_bib421","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1561\/101.00000102","article-title":"Benefit transfer of environmental and resource values: progress, prospects and challenges","volume":"12","author":"Johnston","year":"2018","journal-title":"Int Rev Environ Resour Econ"},{"key":"10.1016\/j.jval.2025.06.004_bib422","series-title":"Benefit Transfer of Environmental and Resource Values: A Guide for Researchers and Practitioners","first-page":"19","article-title":"Introduction to Benefit Transfer Method","author":"Johnston","year":"2015"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib423","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ecolecon.2006.03.018","article-title":"Measurement, generalization, and publication: sources of error in benefit transfers and their management","volume":"60","author":"Rosenberger","year":"2006","journal-title":"Ecol Econ"},{"key":"10.1016\/j.jval.2025.06.004_bib424","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079890","article-title":"ROBVALU: a tool for assessing risk of bias in studies about people\u2019s values, utilities, or importance of health outcomes","volume":"385","author":"Karam","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2025.06.004_bib425","doi-asserted-by":"crossref","DOI":"10.1016\/j.wre.2020.100164","article-title":"The impacts of three dimensions of (dis)similarities on water quality benefit transfer errors","volume":"32","author":"Carolus","year":"2020","journal-title":"Water Resour Econ"},{"key":"10.1016\/j.jval.2025.06.004_bib426","series-title":"Transferring landscape values using discrete choice experiments: Isis meta-analysis an option?","first-page":"1","year":"2014"},{"issue":"11","key":"10.1016\/j.jval.2025.06.004_bib427","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2165\/00019053-200826110-00003","article-title":"Methods for the meta-analysis of willingness-to-pay data","volume":"26","author":"Van Houtven","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2025.06.004_bib428","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40271-024-00673-y","article-title":"How to present a decision object in health preference research: attributes and levels, the decision model, and the descriptive framework","volume":"18","author":"M\u00fchlbacher","year":"2025","journal-title":"Patient"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib429","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40271-025-00728-8","article-title":"Transferability of preferences; for better or \u2026.?","volume":"18","author":"Veldwijk","year":"2025","journal-title":"Patient"},{"issue":"2","key":"10.1016\/j.jval.2025.06.004_bib430","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40271-025-00727-9","article-title":"What next for the science of patient preference? interoperability, standardization, and transferability","volume":"18","author":"Marsh","year":"2025","journal-title":"Patient"},{"key":"10.1016\/j.jval.2025.06.004_bib431","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100653","article-title":"Heterogeneity in individual preferences for HIV testing: a systematic literature review of discrete choice experiments","volume":"29-30","author":"Sharma","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525024088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525024088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:14:06Z","timestamp":1777608846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525024088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":428,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1098301525024088"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.06.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do We Always Need a New Preference Study? A Scoping Review of Promising Research Areas for Meta-Analyses and Benefit Transfers of Patient Preference Studies","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}